Oncologists won't be able to prescribe Zantrene and generic carfilzomic together because Amgen is about to make RAC an offer too good to refuse to prevent this option from being trialled in the clinic.
If this disturbs you, please look at IXC, but you won't be happy about that either.
Ann: Expanded Heart Protection Discovery for Zantrene, page-153
-
- There are more pages in this discussion • 234 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.090(6.25%) |
Mkt cap ! $259.8M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.57 | $1.46 | $198.7K | 131.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5533 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.54 | 1000 | 1 |
View Market Depth
| Last trade - 14.29pm 12/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |